Not available
Quote | Revance Therapeutics Inc. (NASDAQ:RVNC)
Last: | $2.68 |
---|---|
Change Percent: | -0.41% |
Open: | $2.43 |
Close: | $2.68 |
High: | $2.68 |
Low: | $2.41 |
Volume: | 1,090,224 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Revance Therapeutics Inc. (NASDAQ:RVNC)
2024-06-20 16:40:55 ET Summary Revance Therapeutics, Inc. operates in the aesthetics and therapeutics markets, selling Daxxify and RHA Collection of dermal fillers in the U.S. Despite positive guidance for 2024, the Revance stock price has fallen by nearly 70% year-to-date, facing...
2024-05-10 12:57:54 ET Gainers: Novavax NVAX +106% . AEye LIDR +67% . ITeos Therapeutics ITOS +48% . Sensus Healthcare SRTS +35% . Inseego Corp INSG +32% . Sweetgreen SG +33% . Organogenesis Holdings ORGO +33% . Caredx CDNA +32...
Message Board Posts | Revance Therapeutics Inc. (NASDAQ:RVNC)
Subject | By | Source | When |
---|---|---|---|
.. does anybody have an indication what the | rock mountain | investorshub | 05/01/2023 6:49:11 PM |
1Q23 Botox sales broken down every which way: | DewDiligence | investorshub | 04/27/2023 2:22:44 PM |
Diabetes and Eli Lilly reports booming | stocksrising | investorshub | 04/27/2023 11:44:59 AM |
Daxxi seems to have gotten the imprimatur of | marthambles | investorshub | 04/26/2023 12:50:09 PM |
The biggest trend in Medspas now (by far) | boraborak38 | investorshub | 04/22/2023 1:49:09 AM |
News, Short Squeeze, Breakout and More Instantly...
Revance Therapeutics Inc. Company Name:
RVNC Stock Symbol:
NASDAQ Market:
Revance Therapeutics Inc. Website:
- Total net product revenue (DAXXIFY® and RHA® Collection) of $51.7 million, a YoY increase of 13%. - DAXXIFY® net revenue of $22.1 million, after a reduction of $2.0 million related to a consumer coupon program. - Toxin market share increased from 3.0% in Q4’23 to 3...
Conference Call Scheduled for Thursday, May 9, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (NASDAQ: RVNC), today announced that the company will release first quarter 2024 financial results on Thursday, May 9, 2024, after the close of market. Revance will host a corresponding confe...
– Two presentations highlighting data on DAXXIFY® for the treatment of cervical dystonia, including a new analysis from ASPEN trials assessing patient-desired retreatment intervals and one abstract examining the influence of DAXXIFY’s formulation on clinical performance ...